INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION COMMERCIAL PRODUCT ADDENDUM For DOXOPHOS
Exhibit 10.26
[***] INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION
For DOXOPHOS
THIS COMMERCIAL PRODUCT ADDENDUM is an addendum to that certain Master Manufacturing and Supply Agreement of the 25th of April, 2014 by and between XXXXXX ONCOLOGY GMBH (“Baxter”), a German company having a place of business at Xxxxxxxxxxx 0, 00000 Xxxxx / Xxxxxxxxxx, Xxxxxxx, and OASMIA PHARMACEUTICAL AB, a Swedish corporation, having offices at Xxxxxxxxxxx 0, XX 000 00 Xxxxxxx Xxxxxx (the “Commercial Supply Agreement”) and shall commence on the 20th day of May, 2014 (“Commercial Product Addendum Effective Date”) and expire at the end of 19th day of May 2019 (the “Commercial Product Addendum Term”).
This Commercial Product Addendum may be executed in one or more counterparts, each of which shall be deemed an original and all of which shall constitute the same instrument. Upon its execution, this Commercial Product Addendum shall become effective and shall be incorporated by reference into the Master Manufacturing and Supply Agreement.
| By: | /s/ Xx. Xxxxxxxx Xxxxxxx | By: | /s/ Xxxxxx Xxxxxxx | |
| Name: | Xx. Xxxxxxxx Xxxxxxx | Name: | Xxxxxx Xxxxxxx | |
| Title: | VP of Manufacturing BPS | Title: | CEO | |
| By: | /s/ Xxxx Xxxxxx | |||
| Name: | Xxxx Xxxxxx | |||
| Title: | EVP |
EXHIBIT A to Commercial Product Addendum for DOXOPHOS
Product and Presentation, Anticipated Regulatory Approval Date and Applicable Confidentiality Agreement
| Product | Presentation | |
| DOXOPHOS | DOXOPHOS, *** |
Anticipated Regulatory Approval Date for a Baxter supplied Product (Section 8.5): December, 2018.
Applicable Confidentiality Agreement (Section 18.2):
CONFIDENTIAL
| 2 |
[***] INDICATES CONFIDENTIAL PORTION HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION
EXHIBIT B to Commercial Product Addendum for DOXOPHOS
Initial Long Range Forecast, Annual Obligation and Supply Obligation
The Initial Long Range Forecast is as follows:
| Year | Forecast | |
| *** | ***units (*** Batches) | |
| *** | *** units (*** Batches) | |
| *** | *** units (*** Batches) | |
| *** | *** units (*** Batches) | |
| *** | *** units (*** Batches) |
The Client’s Annual Obligation and Xxxxxx’x Supply Obligation for each and every year in the Commercial Product Addendum Term is as follows:
| Contract Year | Client’s Annual Obligation | Xxxxxx’x Supply Obligation | ||
| *** | ***units (*** Batches) | ***units (*** Batches) | ||
| *** | ***units (*** Batches) | ***units (*** Batches) | ||
| *** | ***units (*** Batches) | ***units (*** Batches) | ||
| *** | ***units (*** Batches) | ***units (*** Batches) | ||
| *** | ***units (*** Batches) | ***units (*** Batches) |
CONFIDENTIAL
| 3 |
